Cartesian Therapeutics Inc
RNAC
Company Profile
Business description
Cartesian Therapeutics Inc is a clinical-stage biopharmaceutical company. The company uses its ImmTOR immune tolerance platform, which is designed to give rise to antigen-specific immunity, mitigating unwanted immune responses. The company leverages its proprietary technology and manufacturing platform to introduce one or more mRNA molecules into cells to enhance their function.
Contact
7495 New Horizon Way
FrederickMD21703
USAT: +1 301 348-8698
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
66
Stocks News & Analysis
stocks
Ahead of Earnings, is Apple stock a buy, a sell, or fairly valued?
Following strong holiday sales and a recent AI deal, here’s what we’re watching for in Apple’s earnings report.
stocks
What to expect from these major ASX shares this earnings season
Our analysts answer key questions on major ASX shares ahead of earnings.
stocks
Procter & Gamble earnings: Frigid sales and margins don’t suggest cracks in its standing
North America was a notable blemish, down 2% on an organic basis.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,189.90 | 15.70 | 0.17% |
| CAC 40 | 8,143.05 | 5.84 | -0.07% |
| DAX 40 | 24,900.71 | 44.24 | 0.18% |
| Dow JONES (US) | 49,098.71 | 285.30 | -0.58% |
| FTSE 100 | 10,143.44 | 6.61 | -0.07% |
| HKSE | 26,710.84 | 38.67 | -0.14% |
| NASDAQ | 23,501.24 | 65.22 | 0.28% |
| Nikkei 225 | 52,887.28 | 959.59 | -1.78% |
| NZX 50 Index | 13,434.09 | 14.15 | -0.11% |
| S&P 500 | 6,915.61 | 2.26 | 0.03% |
| S&P/ASX 200 | 8,860.10 | 15.00 | 0.17% |
| SSE Composite Index | 4,138.46 | 2.30 | 0.06% |